MedWatch
This article was originally published in The Tan Sheet
Executive Summary
FDA posts message for health professionals Aug. 25 asking them to report any serious adverse events that occur with use of dietary supplements containing GBL, GHB or BD to the MedWatch database. FDA has issued warnings to consumers of the dangers of gamma butyrolactone, gamma hydroxybutyric acid and 1,4 butanediol through "Talk Papers" and flyers sent to health care professional organizations and publications, school boards and health club associations (1"The Tan Sheet" June 28, p. 5). The agency has asked manufacturers to cease marketing dietary supplements containing the ingredients, for which it has safety concerns
You may also be interested in...
FDA Flyers Warn Consumers Of Dangerous BD, GBL, GHB Supplements
FDA sent flyers to health care professional organizations and publications, school boards and health club associations June 15 warning of the danger from dietary supplements containing 1,4 butanediol (BD), gamma butyrolactone (GBL) and gamma hydroxybutyric acid (GHB). The agency asked the organizations to disseminate the flyers in prominent places and publish the information in publications, magazines or association/company newsletters.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands